Research Topic

Recent Advances in Endothelial Progenitor Cells Toward Their use in Clinical Translation

About this Research Topic

Since endothelial progenitor cells (EPCs) were first described in 1997, there has been significant debate surrounding their definition and roles; but also agreement in their potential to develop as biomarkers and cytotherapies. EPCs participate in vascular repair and postnatal angiogenesis by differentiating into endothelial cells or by producing pro–angiogenic growth factors. Various subtypes of EPCs have been studied, such as CD34+VEGFR2+ blood circulating cells, cultured endothelial colony forming cells (ECFCs), and myeloid angiogenic cells (MACs). EPCs have therapeutic potential for revascularisation and vascular repair in ischemic diseases such as myocardial infarction and diabetic vascular complications. In this Research Topic, we would like to compile evidence to enable their translation including strategies to enhance the number, homing ability to the injury site and function of EPCs.

We welcome all forms of submissions: original research, review and method articles, clinical trials and case reports.


Keywords: endothelial progenitor cells, EPC


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Since endothelial progenitor cells (EPCs) were first described in 1997, there has been significant debate surrounding their definition and roles; but also agreement in their potential to develop as biomarkers and cytotherapies. EPCs participate in vascular repair and postnatal angiogenesis by differentiating into endothelial cells or by producing pro–angiogenic growth factors. Various subtypes of EPCs have been studied, such as CD34+VEGFR2+ blood circulating cells, cultured endothelial colony forming cells (ECFCs), and myeloid angiogenic cells (MACs). EPCs have therapeutic potential for revascularisation and vascular repair in ischemic diseases such as myocardial infarction and diabetic vascular complications. In this Research Topic, we would like to compile evidence to enable their translation including strategies to enhance the number, homing ability to the injury site and function of EPCs.

We welcome all forms of submissions: original research, review and method articles, clinical trials and case reports.


Keywords: endothelial progenitor cells, EPC


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Topic Editors

Loading..

Submission Deadlines

06 March 2018 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..

Topic Editors

Loading..

Submission Deadlines

06 March 2018 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..
Loading..

total views article views article downloads topic views

}
 
Top countries
Top referring sites
Loading..

Comments

Loading..

Add a comment

Add comment
Back to top